Thermo Fisher Scientific NAGA Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1 µg/mL

-

Immunocytochemistry (ICC/IF)

5-15 µg/mL

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Sheep / IgG

Class

Polyclonal

Type

Antibody

Immunogen

CHO-derived recombinant human alpha-N-acetylgalactosaminidase/NAGA Leu18-Gln411 if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:NAGA,uniProtId:P17050-1,ncbiNodeId:9606,antigenRange:18-411,antigenLength:411,antigenImageFileName:PA5-47863_NAGA_P17050-1_Sheep.svg,antigenImageFileNamePDP:PA5-47863_NAGA_P17050-1_Sheep_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Concentration

0.2 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS with 5% trehalose

Contains

No Preservative

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2609331

Product Specific Information

In direct ELISAs, less than 2% cross-reactivity with recombinant human alpha -Galactosidase A is observed.

Reconstitute in sterile PBS to a final concentration of 0.2 mg/mL.

Target Information

NAGA (N-acetylgalactosaminidase, alpha), also known as alpha-galactosidase B or GALB, is a 411 lysosomal protein belonging to the glycosyl hydrolase 27 family that may exist as a homodimer and plays a critical role in glycolipid breakdown. NAGA encodes alpha-N-acetylgalactosaminidase, a lysosomal enzyme, which cleaves alpha-N-acetylgalactosaminyl groups from glycoconjugates. Mapping to human chromosome 22q13. 2, NAGA defects are the cause of an autosomal recessive disorder with three phenotypes, known as Schindler disease (types I, II and III) or NAGA deficiency (types I, II and III). Characterized by neurologic manifestations that range in severity, Schindler disease type I is the most severe form, followed by type III, which may have mild-to-moderate effects. Schindler disease type II, also known as Kanzaki disease, is characterized by mild intellectual impairment and angiokeratoma corporis diffusum.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.